Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Delcath Systems, Inc. (DCTH)

16.46 +0.12 (+0.73%)
At close: August 31 at 4:00:00 PM EDT
16.50 +0.04 (+0.24%)
After hours: August 31 at 6:10:28 PM EDT
Trade DCTH on Coinbase
Chart Range Bar
Loading chart for DCTH
Chart does not reflect overnight price.
  • Previous Close 16.34
  • Open 16.27
  • Bid 11.83 x 200
  • Ask 17.80 x 100
  • Day's Range 16.10 - 16.48
  • 52 Week Range 8.12 - 17.42
  • Volume 402,597
  • Avg. Volume 568,130
  • Market Cap (intraday) 571.142M
  • Beta (5Y Monthly) 0.52
  • PE Ratio (TTM) 1,646.00
  • EPS (TTM) 0.01
  • Earnings Date (est.) Nov 3, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 24.00

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.

www.delcath.com

156

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Performance Overview

Trailing total returns as of 8/31/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

DCTH
62.97%
S&P 500 (^GSPC)
12.28%

1-Year Return

DCTH
49.36%
S&P 500 (^GSPC)
18.98%

3-Year Return

DCTH
258.61%
S&P 500 (^GSPC)
70.51%

5-Year Return

DCTH
64.60%
S&P 500 (^GSPC)
69.95%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 29.13M
Earnings 2.67M
Profit Margin 9.16%

Q2

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
10M
20M
-5.0%
0.0%
5.0%
10.0%

Analyst Insights

View More

Analyst Price Targets

21.00
24.00 Average
16.46 Current
32.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/7/2026
Analyst HC Wainwright & Co.
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 30 -> 32

Statistics

View More

Valuation Measures

Annual
As of 8/27/2026
  • Market Cap

    568.37M

  • Enterprise Value

    474.93M

  • Trailing P/E

    1.64k

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    6.83

  • Price/Book (mrq)

    4.69

  • Enterprise Value/Revenue

    4.98

  • Enterprise Value/EBITDA

    294.18

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.56%

  • Return on Assets (ttm)

    -0.89%

  • Return on Equity (ttm)

    0.47%

  • Revenue (ttm)

    95.42M

  • Net Income Avi to Common (ttm)

    532k

  • Diluted EPS (ttm)

    0.01

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    95.9M

  • Total Debt/Equity (mrq)

    2.03%

  • Levered Free Cash Flow (ttm)

    18.12M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

16.46 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: